2,4-di(benzyloxycarbonyl)butylbenzylphosphinic acid | 200698-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-di(benzyloxycarbonyl)butylbenzylphosphinic acid
• 英文别名: dibenzyl 2-[(benzyloxyphosphinyl)methyl]pentanedioate；2-benzyloxyphosphinoylmethyl-pentanedioic acid dibenzyl ester
• CAS: 200698-35-7
• 化学式: C₂₇H₂₉O₆P
• 分子量: 480.497
• InChiKey: BSJTYZOEFCPKDT-UHFFFAOYSA-N

物化性质

• 沸点：
  610.2±65.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.56
• 重原子数：
  34.0
• 可旋转键数：
  13.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  78.9
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2,4-di(benzyloxycarbonyl)butylbenzylphosphinic acid 在 palladium dihydroxide 氢气 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、482.63 kPa 条件下， 反应 26.0h， 生成 (2R)-2-[[[(2R)-2,4-dicarboxybutyl]-hydroxyphosphoryl]methyl]pentanedioic acid
  参考文献：
  名称：

  Dual Function Glutamate-Related Ligands:  Discovery of a Novel, Potent Inhibitor of Glutamate Carboxypeptidase II Possessing mGluR3 Agonist Activity

  摘要：

  DOI：

  10.1021/jm9905559
• 作为产物：
  描述：

  dibenzyl 2-methylenepentanedioate 在 4-二甲氨基吡啶 、 三甲基氯硅烷 、 氨 、 次磷酸 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 2,4-di(benzyloxycarbonyl)butylbenzylphosphinic acid
  参考文献：
  名称：

  [EN] BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES
  [FR] CONJUGUÉS INHIBITEURS DE GCPII-ACIDE BILIAIRE POUR TRAITER DES MALADIES INFLAMMATOIRES

  摘要：

  GCPII抑制剂包括2-(磷酸甲基)戊二酸（2-PMPA）与胆酸结合，并且它们用于治疗与GCPII水平升高相关的疾病或症状，包括炎症性肠病。

  公开号：

  WO2021155167A1

文献信息

• DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME
  申请人：Baker, JR. James R.

  公开号：US20090088376A1

  公开（公告）日：2009-04-02

  The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).

  本发明涉及新型治疗和诊断树状分子。具体而言，本发明涉及基于树状分子的组合物和系统，用于疾病诊断和治疗（例如癌症诊断和治疗）。该组合物和系统包括一个或多个成分，用于靶向、成像、感知和/或提供治疗或诊断材料，并监测细胞或组织（例如肿瘤）对治疗的反应。
• Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors
  作者：Paul F. Jackson、Kevin L. Tays、Keith M. Maclin、Yao-Sen Ko、Weixing Li、Dil Vitharana、Takashi Tsukamoto、Doris Stoermer、Xi-Chun M. Lu、Krystyna Wozniak、Barbara S. Slusher

  DOI：10.1021/jm0001774

  日期：2001.11.1

  A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.
• WO2008/8483
  申请人：——

  公开号：——

  公开（公告）日：——
• LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE
  申请人：Kozikowski Alan P.

  公开号：US20080176821A1

  公开（公告）日：2008-07-24

  The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.
• Dendrimer based compositions and methods of using the same
  申请人：Shi Xiangyang

  公开号：US20090053139A1

  公开（公告）日：2009-02-26

  The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).